This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.

开始日期2026-04-15

申办/合作机构

迪哲（江苏）医药股份有限公司

NCT07525466

/ Recruiting临床1/2期IIT

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH): a Prospective, Multi-center, Single Arm, Phase Ib/II Clinical Trial

Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patients develop secondary hemophagocytic lymphohistiocytosis (NKTCL-HLH), a life-threatening complication with median survival <2 months and mortality over 90%. Current treatments fail to simultaneously control lymphoma and hyperinflammation, with poor tolerance and high resistance.
The JAK/STAT pathway drives EBV-induced inflammation and tumor progression. Golidocitinib, a selective JAK1 inhibitor, demonstrates potent anti-NKTCL activity and rapid inflammation control. Liposomal mitoxantrone offers targeted efficacy with lower toxicity, while etoposide, methylprednisolone, and pegaspargase provide synergistic anti-tumor and anti-HLH effects.
This study proposes the novel MEPL-G regimen (liposomal mitoxantrone, etoposide, methylprednisolone, pegaspargase, golidocitinib) for NKTCL-HLH. By targeting both HLH and NKTCL, this combination aims to achieve rapid disease control, improve tolerance, and prolong survival, addressing the unmet critical clinical need for this high-risk population.

开始日期2026-04-01

申办/合作机构

首都医科大学附属北京同仁医院

NCT07300514

/ Recruiting临床3期IIT

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma in Complete or Partial Remission After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Phase III Clinical Study.

This is a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating golidocitinib as maintenance therapy in adult patients with peripheral T-cell lymphoma (PTCL) who achieved complete response (CR) or partial response (PR) after first-line systemic chemotherapy and are not candidates for hematopoietic stem cell transplantation (HSCT) or decline HSCT. Eligible patients with histologically confirmed PTCL subtypes (PTCL-NOS, ALK-positive anaplastic large cell lymphoma [ALK-ALCL], angioimmunoblastic T-cell lymphoma [AITL], or follicular helper T-cell phenotype PTCL [FTCL/PTCL-TFH]) according to the 2016 WHO classification will be randomized 1:1 to receive oral golidocitinib or matching placebo.
Study treatment is given at 150 mg every other day in 28-day cycles for up to 2 years or until disease progression, unacceptable toxicity, start of new anti-lymphoma therapy, withdrawal of consent, or study termination. At 12 months, patients who achieve complete metabolic response on PET-CT and minimal residual disease (MRD)-negative status by ctDNA may discontinue maintenance, whereas others continue treatment up to 24 months. After treatment discontinuation, patients will be followed for disease status and survival for up to approximately 13 additional cycles. The primary endpoint is progression-free survival (PFS) assessed by investigators per Lugano 2014 criteria. Key secondary endpoints include overall survival, response rates, duration of response, time to next anti-lymphoma therapy, MRD dynamics by ctDNA, and safety.

开始日期2026-03-27

申办/合作机构

复旦大学

100 项与戈利昔替尼相关的临床结果

登录后查看更多信息

100 项与戈利昔替尼相关的转化医学

登录后查看更多信息

100 项与戈利昔替尼相关的专利（医药）

登录后查看更多信息

256

项与戈利昔替尼相关的文献（医药）

2026-05-01·MedComm

XIAP Deficiency Impairs Colonic Tuft Cell Development and Predisposes to Crohn's Disease

Article

作者: Nie, Changjun ; Geng, Lanlan ; Yang, Xi ; Huang, Jiwei ; Qi, Yuyin ; Li, Lili ; Peng, Xiang ; Vince, James E. ; Wang, Qiuhua ; Zhang, Min ; Chen, Hanhan ; Zhi, Min ; Chen, Zhanghua ; Zhang, Yuxia ; Zhong, Kanghua ; Zhou, Wenhao ; Wu, Huibo ; Wang, Wei ; Xian, Huifang ; Zhang, Li ; Zou, Ming ; Tang, Ning ; Fang, Rongli ; Tang, Chaorui ; Kanegane, Hirokazu ; Huang, Lei ; Zhao, Xiaodong ; Zhu, Jianheng ; Tan, Liren

ABSTRACT:

A substantial proportion of patients with X‑‐linked inhibitor of apoptosis (XIAP) deficiency develop severe and treatment‑‐refractory Crohn's disease (CD). Although hematopoietic stem cell transplantation (HSCT) remains the only curative option for these patients, its outcomes are suboptimal, with a long‑‐term survival rate of only 50%. Therefore, identifying novel therapeutic targets is crucial to bridge this unmet clinical need. Here, we demonstrate that the abundance of tuft cells is reduced in both XIAP‐deficient CD patients and Xiap knockout ( Xiap−/− ) mice. Mechanistically, XIAP deficiency reduces TLE4 ubiquitination, resulting in elevated TLE4 protein levels and consequent suppression of Wnt/β‑‐catenin–ASCL2 signaling, which is critical for secretory lineage differentiation. Tuft cell deficiency may increase susceptibility to microbial dysregulation, thereby promoting intestinal inflammation. Furthermore, we demonstrate that JAK inhibition promotes tuft cell regeneration and ameliorates mucosal inflammation in Xiap−/− mice. Consistently, in an XIAP‑‐deficient CD patient, treatment with a selective JAK1 inhibitor effectively increased tuft cell proportion and alleviated colonic symptoms. In conclusion, our study identifies tuft cell deficiency as a trigger of intestinal pathology in XIAP‑‐deficient Crohn's disease and suggests JAK inhibition as a promising therapeutic strategy.

2026-05-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of selective JAK1/2 inhibitor H018, a phase II agent with demonstrated preclinical anti-rheumatoid arthritis activity

Article

作者: Wang, Peng ; Yang, Jing ; Wang, Hongfan ; Li, Shuai ; Zhu, Haifeng ; Su, Mei

Janus kinase (JAK) inhibitors represent a class of oral therapeutics for rheumatoid arthritis (RA), demonstrating superior clinical efficacy compared to conventional disease-modifying antirheumatic drugs (DMARDs). However, pan-JAK inhibitors are associated with side effects such as infections and hematologic toxicity, and selective JAK inhibitors exhibit diminished efficacy. Guided by the dual mechanism of JAK1 selectivity driving efficacy and JAK2 inhibition to enhance anti-inflammatory effects, we employed rational drug design to develop the highly selective JAK1/2 inhibitor H018 (RAI-20), intending to improve the drug safety while simultaneously managing adverse effects within a reasonable range. Compound RAI-20 exhibited significantly optimized targeting properties, with kinase inhibitory activity and isoform subtype selectivity comprehensively surpassing clinically approved JAK1 inhibitor Filgotinib, thereby establishing a novel strategic strategy for JAK1/2 inhibitor design. Notably, compound RAI-20 demonstrated distinct advantages in key pharmacokinetic and safety assessment parameters, including enhanced plasma stability, significantly improved systemic exposure (AUC) and prolonged duration of half-life. Furthermore, RAI-20 elicited potent, dose-dependent protection against RA in the collagen-induced arthritis (CIA) model, and its efficacy exceeds some marketed JAK inhibitors. Currently, compound RAI-20 has progressed to Phase II clinical trials and is poised to be a potential RA treatment option that combines high efficacy with low toxicity.

2026-05-01·JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Article

作者: Bunick, Christopher G. ; Guttman‐Yassky, Emma ; Platt, Andrew M. ; Shahriari, Mona ; Levy, Gweneth F. ; Silverberg, Jonathan I. ; Weidinger, Stephan ; Dilley, Deanne M. ; Gao, Xinghua ; Irvine, Alan D. ; D'Andrea, Elvira ; Katoh, Norito ; Vigna, Namita ; Teixeira, Henrique D.

Abstract:

Background:

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by eczematous lesions, dry skin and intense pruritus. Upadacitinib, a selective JAK1 inhibitor approved for moderate‐to‐severe AD in adults and adolescents, is a once‐daily oral treatment.

Objectives:

To evaluate the long‐term safety profile of the treatment of moderate‐to‐severe AD with upadacitinib 15 mg (UPA15) or 30 mg (UPA30) across 6 years.

Methods:

Safety data for adverse events (AEs), including treatment‐emergent adverse events (TEAEs) and adverse events of special interest (AESIs) from three global phase 3 studies (MeasureUp 1, MeasureUp 2 and ADUp), were analysed. Data were included for all adolescent and adult patients (12–75 years) receiving at least 1 dose of UPA15 or UPA30 across 6 years.

Results:

Serious adverse event rates were similar for UPA15 (6.6 events [E] per 100 patient‐years [PY]) and UPA30 (7.4 E/100 PY). Nasopharyngitis was the most frequently reported adverse event (UPA15, 9.8 E/100 PY; UPA30, 9.3 E/100 PY) excluding COVID‐19. Event rates for serious infections were similar for both groups (UPA15, 2.2 E/100PY; UPA30, 2.6 E/100 PY). Rates of most AESIs were similar between UPA15 and UPA30, except for those known to be dose dependent: herpes zoster, hepatic disorder, neutropenia and CPK elevation. Adjudicated major adverse cardiovascular event incidence rates were 0.2 n/100PY and <0.1 n/100PY for UPA15 and UPA30, respectively. Adjudicated venous thromboembolic event incidence rates were 0.1 n/100PY for both UPA15 and UPA30. Rates of malignancy excluding non‐melanoma skin cancer were 0.3 n/100PY for UPA15 and 0.5 n/100PY for UPA30. Rates of lymphoma were <0.1 n/100PY for both groups. Rates of TEAEs leading to death were low (<0.1 E/100PYs and 0.1 E/100 PYs for UPA15 and UPA30, respectively).

Conclusions:

This analysis provides information about the long‐term safety of upadacitinib in AD, with no new important safety signals identified for up to 6 years.

588

项与戈利昔替尼相关的新闻（医药）

2026-06-07

·小林科创观察

【小林全球科创早报】2026.6.8 星期一

🔵 TMT 科技·媒体·电信（6条） 1、NVIDIA Vera Rubin 平台全面投产，COMPUTEX 2026 释放全栈 AI 信号 6月1日至5日，在 COMPUTEX 2026 展会上，英伟达 CEO 黄仁勋正式宣告下一代 AI 超级芯片平台 Vera Rubin 全面投入生产，专为智能体 AI（Agentic AI）设计，大规模智能体吞吐量较 Grace Blackwell 提升 10 倍，预计今年第三季度发货。同期，英伟达联合微软与联发科发布 RTX Spark AIPC 芯片（3nm），搭载 GB300 Grace Blackwell Ultra 的 DGX Station for Windows 同步亮相，标志英伟达从 GPU 向 CPU+AI PC 全栈基础设施的战略跃迁。 📎 来源：IT之家｜ EET China（双源核验） 2、SK 海力士五年产能翻倍 + 与台积电深化 HBM4 全栈合作 6月2日，SK 集团董事长崔泰源在 COMPUTEX 2026 期间先后会见英伟达 CEO 黄仁勋与台积电董事长魏哲家，宣布两大战略决策：SK 海力士五年内晶圆产能翻番，2026年 HBM 产能已售罄；自 HBM4 起将基底芯片生产全面外包至台积电（12nm），HBM4E 导入 3nm 工艺。SK 海力士同步展出 HBM4E 48GB 12Hi 样品，带宽达 4.0 TB/s，领先三星。 📎 来源：搜狐｜新浪财经（双源核验） 3、宇树科技科创板 IPO 过会，73 天极速冲刺"具身智能第一股" 6月1日，上交所上市审核委员会审议结果显示宇树科技首发符合发行条件，从受理到过会仅 73天，刷新科创板最快纪录。公司拟募资 42.02 亿元用于智能机器人模型及本体研发，2025年人形机器人出货量超 5500 台居全球第一。6月2日审核状态已变更为"提交注册"。 📎 来源：中国网 4、Anthropic 秘密提交 IPO，估值逼近万亿美元 6月1日，AI 巨头 Anthropic 正式向美国 SEC 秘密提交 S-1 注册声明，启动 IPO 进程。此前5月28日，Anthropic 刚完成 650 亿美元 H 轮融资，投后估值达 9650 亿美元（约合人民币 6.9 万亿元），超越 OpenAI 约 8520 亿美元的估值，成为全球最高估值 AI 初创公司。 📎 来源：腾讯新闻｜虎嗅（双源核验） 5、9 款国产 AI 芯片通过国家安全测评，全部获评 I 级 5月29日，中国信息安全测评中心与国家保密科技测评中心联合发布《安全可靠测评结果公告（2026年第2号）》，首次在安全可靠认证框架下设立"人工智能训练推理芯片"品类，华为昇腾、阿里平头哥、海光等 7家企业共 9 款芯片全部获评最高安全可靠等级 I 级，标志着国产 AI 算力芯片正式纳入国家信创安全认证体系。 📎 来源：腾讯新闻｜搜狐（双源核验） 6、华为等中国科技巨头加速自研 ASIC 芯片，应对美国禁令摩根士丹利 5月研报显示，受美国先进半导体出口管制影响，华为、阿里等中国科技巨头正加速自研专用 AI 芯片（ASIC），预计 2026 年华为昇腾系列将占据国内 AI 加速芯片市场 62% 的份额。2025年中国 AI 服务器市场共交付 400 万颗 AI GPU，其中国产芯片占比已达 **41%**。 📎 来源：快科技｜ OFweek（双源核验）💲 FinTech 金融科技（3条） 1、澳门正式接入 mBridge 多边央行数字货币桥，11 家银行全面开通跨境交易 6月1日，中国人民银行副行长陆磊在澳门宣布：澳门正式完成与多边央行数字货币桥（mBridge）项目的系统对接，成为继中国内地、香港、泰国、阿联酋及国际清算银行之后的第六个成员。6月2日起，澳门 11 家本土银行正式获批开展 mBridge 真实跨境交易。交通银行澳门分行完成两项里程碑：联合澳门工艺有限公司完成数字澳门元跨境汇款，携手远东宏信完成 5 亿元数字人民币跨境收款。此前重庆已落地 35.54 亿元 mBridge 大额跨境业务，系西部地区首笔资本项下规模化数币跨境项目。 📎 来源：新华网｜百度百家号（双源核验） 2、SpaceX IPO 定价日锁定 6月11日，有望成史上最大 IPO 6月4日，SpaceX 向 SEC 递交的最新 S-1/A 增补文件显示，IPO 发行价将于 6月11日锁定，6月12日在纳斯达克挂牌，代码"SPCX"。目标估值约 1.77 万亿美元，计划募资 750-800 亿美元，若超额配售权全额行使将达 862 亿美元，打破沙特阿美 2019 年创下的 294 亿美元 IPO 纪录。 📎 来源：华尔街见闻｜同花顺（双源核验） 3、八部门联合发布《金融产品网络营销管理办法》，9月30日施行 2026年6月，中国人民银行等八部门联合发布《金融产品网络营销管理办法》，确定于 2026年9月30日正式施行，全面整治互联网平台无证销售金融产品、不当营销等行为，对金融科技企业线上展业合规提出更高要求。 📎 来源：百度百家号🧬 生物医药（7条） 1、信达生物 IBI343 NDA 获 NMPA 受理并优先审评：全球首个 CLDN18.2 靶向 ADC 冲刺上市 6月4日，信达生物（01801.HK）宣布其自主研发的 IBI343（CLDN18.2 靶向 ADC）用于晚期胃癌的新药上市申请（NDA）获 NMPA 正式受理，并被授予优先审评。国际多中心 III 期 G-HOPE-001 研究期中分析达成 PFS 和 OS 双主要终点。IBI343 是全球首个获监管审评受理的 CLDN18.2 靶向 ADC 药物，若获批将填补晚期胃癌后线治疗的重要临床空白。 📎 来源：信达生物官网｜搜狐（双源核验） 2、ASCO 2026 创历史新高：中国学者主导研究入选 95 项，康方依沃西登顶全体大会 2026年 ASCO 年会（5月29日-6月2日）上，中国学者主导的研究入选口头报告等重要环节达 95 项，较2025年74项再创新高。康方生物依沃西单抗成为唯一入选全体大会的中国研究，HARMONi-6 数据 PFS 为 11.14 vs 6.90 个月（HR=0.60），首次披露 OS 阳性结果。此外，6 款双抗 ADC 中 5 款来自中国，中国已占据该赛道全球主导地位。 📎 来源：新华财经｜腾讯新闻（双源核验） 3、信达生物 × 辉瑞达成 105 亿美元战略合作 5月29日，信达生物公告与辉瑞签署全球战略许可及合作协议，围绕 12 个肿瘤早期项目（含 4 个 Co-Co 模式全球共同开发/商业化项目），交易总额达 105 亿美元，首付款 6.5 亿美元。这是中国创新药企迄今最大单笔 BD 交易之一，标志信达全球化战略再进一步。 📎 来源：新浪财经｜东方财富（双源核验） 4、迪哲医药舒沃替尼 ASCO LBA 亮相：全球首个 LBA 展示的 EGFR exon20ins 药物迪哲医药三款 NSCLC 产品在 ASCO 2026 亮相。其中，舒沃替尼国际多中心 III 期"悟空28"研究以最新突破摘要（LBA）口头报告形式亮相，成为全球首个在 ASCO LBA 环节展示的 EGFR exon20ins NSCLC 药物。DZD6008（第四代 EGFR TKI）和戈利昔替尼也分别以口头报告和壁报形式公布数据。 📎 来源：经济观察报｜腾讯新闻（双源核验） 5、FDA 批准全球首款新冠暴露后预防口服药 Xocova 5月30日，FDA 批准盐野义制药的抗病毒药物 Xocova（ensitrelvir）用于 12 岁及以上个体在接触 COVID-19 患者后的暴露后预防（PEP）。这是全球首款获批该适应症的口服新冠抗病毒疗法，填补了暴露后预防领域的关键空白。 📎 来源：同花顺｜腾讯新闻（双源核验） 6、Alnylam × Inceptive 达成 20 亿美元 AI 制药合作 6月3日，RNAi 疗法领导者 Alnylam 与 AI 生物技术公司 Inceptive Nucleics 签署战略合作，首付款约 3000 万美元，总金额最高 20 亿美元。双方将把 Alnylam 二十多年积累的专有数据与 Inceptive 的生成式 AI"生命大模型"整合，加速 siRNA/RNAi 创新药物发现，标志着 AI 驱动 RNA 干扰药物研发进入产业化阶段。 📎 来源：新浪财经｜ Alnylam 官方（双源核验） 7、齐鲁制药 QLS2404 注射液获 CDE 临床受理 6月4日，齐鲁制药 1 类创新生物制品 QLS2404 注射液两项临床试验申请获 CDE 承办受理（受理号 CXSL2600600、CXSL2600601），系该公司本年度又一款原创大分子新药进入临床申报阶段。 📎 来源：百度百家号 📌 本早报内容来源于公开网络资讯，仅供参考，不构成任何投资建议。如需转载请注明来源。

2026-06-05

·PRNewswire

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have been discovered, giving rise to 358 unique fusion-tumor pairings. Patients harboring such fusions generally have a poor prognosis. For advanced solid tumor patients who do not receive targeted therapy, the median overall survival ranges from 10.2 to 12.7 months, and these patients are also at a higher risk of brain metastasis. Meanwhile, the loss of the extracellular domain in NTRK fusions renders antibody-based therapies ineffective. Currently, treatment primarily relies on small-molecule TRK inhibitors that target the kinase domain.1-3 Continue Reading Vcare PharmaTech Innovative Drug Pipeline In terms of tumor type distribution, NTRK fusions are characterized by rare mutations with broad tumor spectrum distribution. On one hand, the incidence of NTRK fusions reaches up to 90% in rare malignancies such as secretory breast carcinoma and infantile fibrosarcoma, and ranges from 5% to 25% in papillary thyroid carcinoma and Spitzoid melanoma. On the other hand, real-world data from approximately 295,000 solid tumor patients worldwide indicate that NTRK fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, NTRK fusion-positive patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma and colorectal cancer make up nearly 50% of all affected cases, representing the key population requiring close clinical attention. In addition, the prevalence of NTRK fusions is higher in East Asian populations, with an overall incidence of approximately 0.4% among Chinese patients. It is estimated that more than 15,000 new cases of NTRK fusion-positive solid tumors are diagnosed in China each year.4-5 Breaking News: Domestic Next-Generation Tumor-Agnostic Targeted Drug Eratrectinib Approved On June 4, the official website of the NMPA announced that Vcare PharmaTech's Class 1 new drug, Eratrectinib, has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions. Efficacy Breakthrough: Eratrectinib Delivers Comprehensive Clinical Benefits Eratrectinib is a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co.,Ltd.. In pivotal registration clinical trials for patients with NTRK fusion-positive solid tumors, this pan-tumor anticancer agent has demonstrated outstanding efficacy and safety. Registration study results showed an ORR of 68.5% and a DCR of 85.2%. Among patients followed up for more than 6 months, the ORR reached 89.7% and the DCR was 100%, with a mOS of 40.7 months.6 In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission for patients. Furthermore, for patients with baseline brain metastases, the ORR was as high as 87.5%. For patients previously treated with TRK-TKIs, the ORR reached 47.4%, reflecting robust therapeutic efficacy across these patient groups. New Hope for Patients with NTRK Fusion Resistance As a next-generation TRK inhibitor independently developed in China, Eratrectinib delivers durable and deep tumor remission, with potent brain penetration and a favorable overall safety profile. Different from the linear structure of first-generation TRK inhibitors, Eratrectinib features a cyclic molecular structure. Structural optimization reduces off-target risks and effectively prevents the emergence of drug-resistant mutations, endowing the agent with the anti-resistance mechanisms characteristic of second-generation TRK inhibitors. About Vcare PharmaTech Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) was co-founded in 2010 by professors from China Pharmaceutical University and overseas returnee experts. As a commercial-stage innovative biopharmaceutical enterprise empowered by AI for differentiated de novo drug design, the Company is dedicated to the development of novel medicines and cutting-edge therapeutics, and has been accredited as a National Key Specialized, Refined, Differential and Innovative "Little Giant" Enterprise. Headquartered in the Biotech and Pharmaceutical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech owns an intelligent R&D headquarters spanning 21,000 square meters. It has built a full-chain innovation system covering independent new drug R&D and industrialization, ranging from AI-powered differentiated target initiation at the early discovery stage, preclinical candidate identification, integrated collaborative pharmaceutical development to green manufacturing. Boasting a robust talent pipeline, the Company employs over 900 staff members, among whom technical professionals account for more than 84%, including over 200 master's and doctoral degree holders. Such a highly educated, specialized and innovation-driven core R&D workforce underpins the Company's sustained technological breakthroughs and product upgrading. Having engaged in pharmaceutical innovation for 16 years, Vcare PharmaTech adheres to the core strategy of indigenous R&D and innovation, targeting unmet clinical needs via differentiated therapeutic approaches. Centered on addressing treatment resistance, overcoming drug resistance and improving target selectivity, the Company has established a high-quality, diversified and tiered innovative drug pipeline covering major chronic illnesses including cardiovascular and cerebrovascular diseases, inflammatory autoimmune disorders and oncology, with its novel pharmaceutical discoveries positioned for global commercialization. The Company's core pipeline candidates feature prominent competitive edges and promising commercial prospects. Eratrectinib (VC004), a next-generation TRK inhibitor and small-molecule targeted anti-tumor agent indicated for solid tumors driven by NTRK gene fusions, delivers tumor-agnostic therapeutic benefits across a broad spectrum of indications and has obtained marketing approval in China. Sumecigrel Capsule, a novel oral P2Y12 receptor antagonist selected four times for China's National Major Science and Technology Projects, precisely inhibits platelet activation and aggregation to block thrombosis for the prevention and treatment of cardiovascular, cerebrovascular and arterial circulatory disorders; its pivotal confirmatory clinical trials are well underway domestically. VC005, a new-generation highly selective JAK1 inhibitor, is being developed via both oral and topical formulations for full-population treatment of atopic dermatitis with all indications in Phase III clinical trials. The asset is also under clinical development for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases, with robust efficacy and safety data accelerating its clinical progression. Backed by years of technological accumulation, the Company strives to integrate AI capabilities across the entire value chain from early R&D to manufacturing, establishing an AI-enabled premium innovative drug development system and specialized technical platforms. Its R&D platforms have been officially accredited as Nanjing Key Laboratory for AI-Assisted Drug Design and Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry; its AI-directed site-specific enzyme mutation technology has been recognized as Advanced Cleaner Production Technology by Nanjing authorities. Over the past five years, the Company has secured aggregate financing exceeding RMB 1.2 billion, earning strong recognition from the capital market. Moving forward, abiding by its founding mission of "The better Care, The better Medicines", Vcare PharmaTech will keep advancing AI-driven original innovation and cutting-edge pharmaceutical technologies while expanding its footprint across domestic and overseas markets. Leveraging robust R&D strengths to build a differentiated novel drug portfolio, the company commits to delivering superior therapeutic options for patients worldwide and evolving into a globally influential innovative pharmaceutical enterprise. References: Nguyen MA, et al. Pathology. 2023 Aug;55(5):596-609. Jiang T, et al. Acta Pharm Sin B. 2021 Feb;11(2):355-372. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. O'Haire S, et al. Sci Rep. 2023 Mar 13;13(1):4116. Qi C, et al. Int J Cancer. 2023 Dec 1;153(11):1916-1927. Vcare Pharma. Phase II Clinical Study Data of Eratrectinib[R] Commercial Cooperation: Strategic Development Director: Dr. Peng, [email protected] BD Director: Liam, [email protected] SOURCE Vcare PharmaTech 21% more press release views with Request a Demo

上市批准临床2期临床3期临床结果

2026-06-05

·中国药学年鉴

【行业动态】一批肺癌创新药突破性成果来袭

在肺癌领域，国内药企持续突围，它们在临床研究中展现出疗效和安全性数据，充分证明了国产创新药在肺癌领域的研发实力，同时也让国产创新药价值被重新审视。据悉，在近期举办的2026年ASCO年会上，肺癌领域各种突破性成果，密集亮相。如康方生物在2026年美国临床肿瘤学会(ASCO)年会上，公布了依沃西联合化疗对比替雷利珠单抗联合化疗，一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)III期HARMONi-6/AK112-306研究的OS显著阳性结果。研究结果显示，相比替雷利珠单抗联合化疗，依沃西联合化疗可显著延长患者OS。这次康方生物公布的依沃西研究，是全球头个在肺癌领域对比PD-1联合化疗取得OS和PFS双显著阳性结果的III期研究，也是全球头个在sq-NSCLC领域通过统计假设验证取得OS和PFS双显著阳性结果的III期临床研究，展现出PD-1/VEGF作为新一代肿瘤治疗基石药物的潜力。对于康方生物这次公布的依沃西胜出数据，有医药研发人士表示，虽然试验结果并没有超出很大预期，但从临床实践来说是突破性的，证明了在疗效上可以胜出PD-1单抗，这对于整个PD-1/VEGF双抗赛道构成利好。迪哲医药在2026年美国临床肿瘤学会(ASCO)年会上公布了肺癌领域三项研究进展(舒沃哲、DZD6008、高瑞哲)的公告。其中，舒沃哲国际多中心III期“悟空28”研究以突破摘要(LBA)口头报告形式公布，并同步发表于《新英格兰医学杂志》。该研究针对表皮生长因子受体(EGFR)20号外显子插入突变(exon20ins)非小细胞肺癌(NSCLC)一线治疗，结果显示舒沃哲单药相较含铂双药化疗，无进展生存期(PFS)中位数达10.3个月(vs化疗组7.5个月，HR=0.65，P=0.0008)；客观缓解率(BoR)为68.1%(vs化疗组35.4%)，中位缓解持续时间(DoR)为11.2个月(vs化疗组7.1个月)。 DZD6008作为四代EGFR TKI，其研究数据显示，在治疗EGFR C797X突变的三代EGFR TKI耐药NSCLC中，82.1%患者肿瘤缩小；40mg和60mg剂量下，6个月无进展生存率(PFS率)分别为70.6%和61.8%，且具备优异的血脑屏障穿透性，在基线存在脑转移的患者中观察到颅内肿瘤缓解，安全性良好。高瑞哲联合抗PD-1抗体研究纳入47例初治晚期无驱动基因突变NSCLC患者，PD-L1高表达患者获益更显著，联合治疗方案耐受性良好，免疫相关不良事件(irAE)大幅减轻。同源康医药在2026年美国临床肿瘤学会(ASCO)年会上，以新突破性摘要(LBA)口头报告形式，公布了公司自主研发的甲磺酸艾多替尼片(TY-9591)治疗EGFR突变非小细胞肺癌(NSCLC)脑转移患者一线治疗的关键II期ESAONA研究期中分析结果。结果显示：艾多替尼组颅内客观缓解率(iORR)高达95.5%，显著优于奥希替尼组的79.6%，中位颅内无进展生存期(iPFS)尚未达到，而对照组仅为17.51个月(HR=0.46)。肺癌是发病率较高的肿瘤之一。数据显示，2022 年，全球约有 240 万新发肺癌病例。非小细胞肺癌是常见的肺癌类型，中国小细胞肺癌的年新发病例约为16万。面对巨大的患者群体，国内外亟待新型有效治疗手段满足迫切治疗需求。 2026 ASCO 密集落地的多项临床突破，实现从靶点创新、临床设计到头对头优胜的多方位突破，细分领域覆盖多种临床刚需场景。未来，随着多款重磅产品临床数据落地、后续加速申报上市，国产创新药有望推动肺癌治疗用药可及性大幅提升。感谢您阅读《中国药学年鉴》微信平台文章，欢迎各位读者分享、转载、引用。【免责声明】以上内容来源于互联网，旨在传递行业最新资讯，分享药学相关知识，本号不对转载文章的观点负责。文章及图片版权均属原作者所有，如有侵犯相关著作权，请来电（025-83271478）或在本号留言栏告知，我们将及时更正或删除。来源：制药网

100 项与戈利昔替尼相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
外周T细胞淋巴瘤	中国	迪哲（江苏）医药股份有限公司	2024-06-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
广泛期小细胞肺癌	临床2期	中国	迪哲（江苏）医药股份有限公司	2025-10-31
噬血细胞性淋巴组织细胞增多症	临床2期	中国	迪哲（上海）医药有限公司	2025-05-20
PD-L1阳性非小细胞肺癌	临床2期	中国	迪哲（江苏）医药股份有限公司	2024-01-01
复发性T细胞淋巴瘤	临床2期	中国	迪哲（江苏）医药股份有限公司	2022-05-31
塞扎里综合征	临床2期	中国	迪哲（江苏）医药股份有限公司	2021-12-23
EGFR突变的非小细胞肺癌	临床2期	澳大利亚	迪哲（江苏）医药股份有限公司	2018-04-16
克罗恩病	临床前	中国	迪哲（江苏）医药股份有限公司	-
非小细胞肺癌	临床前	英国	AstraZeneca PLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06198907 (JACKPOT33, ASCO2026)	临床2期	PD-L1阳性肺癌一线 PD-L1 positive	47	Golidocitinib 150 mg + Sintilimab 200 mg	憲醖鏇願蓋願膚艱觸繭(顧簾膚選餘醖壓構窪獵) = 窪繭繭簾廠積蓋網齋艱網襯鏇壓觸鑰齋醖艱襯 (顧蓋壓淵願憲餘醖鏇糧 )	积极	2026-05-29
NCT06198907 (JACKPOT33, ASCO2026)	临床2期	PD-L1阳性肺癌一线 PD-L1 positive	47	Golidocitinib 150 mg + Sintilimab 200 mg (PD-L1 high (TPS ≥50%))	憲醖鏇願蓋願膚艱觸繭(顧簾膚選餘醖壓構窪獵) = 衊獵憲構餘鬱衊觸網鬱網襯鏇壓觸鑰齋醖艱襯 (顧蓋壓淵願憲餘醖鏇糧 )	积极	2026-05-29
NCT06739265 (ASH2025)	临床1/2期	外周T细胞淋巴瘤一线	18	Golidocitinib + CHOP	糧襯鏇積構繭夢簾蓋憲(簾艱艱顧積鹽觸繭鹹築) = CMV reactivation was observed in 3 patients (16.6%) and warrants close monitoring 鬱鑰願鬱衊鑰製構鹽網 (獵齋淵鏇夢窪窪繭壓憲 ) 更多	积极	2025-12-06
ASH2025	N/A	外周T细胞淋巴瘤一线	16	Golidocitinib + CHOP-like chemotherapy	鏇憲齋艱獵餘鏇鏇鹽網(廠醖壓襯鏇糧顧網鬱淵) = 顧淵膚選選觸簾積構窪鑰鹹窪淵鑰鑰襯艱積顧 (窪艱憲淵構壓夢壓淵獵 ) 更多	积极	2025-12-06
NCT06701344 (GOAL, ASH2025)	临床2期	肠病相关的T细胞淋巴瘤一线	7	Golidocitinib plus CHOP	網壓壓蓋願廠範襯夢鏇(積鏇鹽艱艱鏇鹹淵鬱顧) = 鹽繭襯齋鹹襯衊繭醖鹹夢餘積鹽鑰衊艱糧願憲 (襯鬱糧廠膚築齋齋遞獵 ) 更多	积极	2025-12-06
ASH2025	N/A	-	16	Golidocitinib monotherapy	齋壓襯繭艱醖齋糧鹽觸(遞範簾壓顧夢範壓構鑰) = 28.6% 鬱淵壓鑰醖顧積淵願選 (顧齋艱夢鏇餘構構簾膚 ) 更多	积极	2025-12-06
NCT06716658 (ASH2025)	临床2期	大颗粒淋巴细胞白血病	16	Golidocitinib 150 mg	鬱醖餘獵顧網顧簾齋壓(築構淵膚積築餘選製簾) = 鬱願襯夢顧壓簾鬱遞蓋衊鹹鹽鹹糧簾廠鬱鹹夢 (鹹衊醖簾鬱鏇衊醖淵鏇 ) 更多	积极	2025-12-06
NCT04105010 (JACKPOT8 part B, ASH2025)	临床2期	外周T细胞淋巴瘤	13	Golidocitinib 150 mg	範觸齋鏇艱襯襯願齋鬱(鹽獵觸鏇鹽積糧夢鑰選) = 顧選願選廠憲蓋鏇鹽顧築簾壓齋簾膚襯範衊鬱 (積淵膚獵製艱艱夢遞鬱, 44.2 ~ 91.9) 更多	积极	2025-12-06
NCT06511869 (JACKPOT26, EHA2025)	临床2期	外周T细胞淋巴瘤维持	48	Golidocitinib 150 mg once daily	糧繭積糧顧糧醖獵廠觸(餘築鹽網選鹽網觸壓願) = 醖繭願鑰鬱廠遞遞襯鏇鹹網願選積艱醖淵醖範 (觸遞壓選簾獵範範蓋窪 )	积极	2025-05-14
NCT06739265 (PB3228, EHA2025)	临床1/2期	外周T细胞淋巴瘤一线	8	Golidocitinib 150 mg QoD + CHOP	觸構醖襯艱壓築製簾鹹(壓選夢顧簾積遞範構鹹) = 願窪鑰鹽衊鹹鬱齋齋願繭廠鑰廠願選積衊範艱 (製簾壓艱餘簾夢鑰壓艱 ) 更多	积极	2025-05-14
NCT06701344 (GOAL, EHA2025)	临床2期	肠病相关的T细胞淋巴瘤 JAK/STAT signaling pathway	7	Golidocitinib 150 mg per day + CHOP	襯遞襯製觸獵衊夢鑰淵(網範廠夢製鑰餘廠願製) = 範醖鹹鑰製鏇範觸獵繭鹹蓋選製餘淵簾餘獵鑰 (鏇蓋夢憲鏇憲鬱淵築構 )	积极	2025-05-14